Choreo LLC acquired a new stake in Affimed (NASDAQ:AFMD – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $54,000. Choreo LLC owned 0.07% of Affimed as of its most recent SEC filing.
Separately, BNP Paribas Financial Markets lifted its position in Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares during the period. 30.82% of the stock is owned by hedge funds and other institutional investors.
Affimed Price Performance
Shares of Affimed stock opened at $3.69 on Friday. Affimed has a 12-month low of $2.23 and a 12-month high of $8.95. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average of $4.41 and a two-hundred day moving average of $5.11.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on Affimed
Affimed Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.
Featured Articles
- Five stocks we like better than Affimed
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Short Selling: How to Short a Stock
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Conference Calls and Individual Investors
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed (NASDAQ:AFMD – Free Report).
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.